On June 16, Pegbio Biopharmaceuticals-B declined 8.23% in regular trading, trading at HK$6.48/share, with turnover of HK$35.48 million. The stock hit a fresh 52-week low amid persistent market pessimism.

The decline was driven by a combination of litigation risk overhang and broad-based weakness across the biotech sector. Since its listing, the stock has retreated significantly from its highs, with a cumulative decline exceeding 85% over the past three months, reflecting sustained erosion in investor confidence.

At the sector level, the biotechnology space traded broadly lower, amplifying selling pressure through sector linkage effects. Among peers, AKESO fell 6.1%, 3SBIO dropped 5.03%, and Innovent Bio slipped 1.81%, while BeiGene edged up 0.13% and SKB Bio gained 0.72%.

Pegbio Biopharmaceuticals is a China-based company focused on developing innovative therapies for chronic diseases. Its lead product PB-119 is a near-commercialization-stage long-acting GLP-1 receptor agonist targeting type 2 diabetes, obesity, and other metabolic diseases.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)